<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844450</url>
  </required_header>
  <id_info>
    <org_study_id>CR108997</org_study_id>
    <secondary_id>75220795NAS1001</secondary_id>
    <nct_id>NCT04844450</nct_id>
  </id_info>
  <brief_title>A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JNJ-75220795</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety and tolerability of single and multiple&#xD;
      subcutaneous (SC) doses of JNJ-75220795.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Signs and Symptoms/ Adverse Events (AEs)</measure>
    <time_frame>Up to Day 182</time_frame>
    <description>Number of participants with treatment-emergent signs and symptoms/adverse events (including allergic reactions/hypersensitivity and local injection site reactions) will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Treatment-emergent adverse events (TEAEs) are defined as AEs with onset or worsening on or after date of first dose of study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Change From Baseline in Vital Signs Abnormalities</measure>
    <time_frame>Baseline, up to Day 168</time_frame>
    <description>Number of participants with change from baseline in vital signs abnormalities including temperature, heart rate, respiratory rate, and blood pressure (supine) will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Change From Baseline in Clinical Laboratory Abnormalities</measure>
    <time_frame>Baseline, up to Day 168</time_frame>
    <description>Number of participants with change from baseline in clinical laboratory abnormalities including hematology, chemistry and urinalysis will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Change From Baseline in Physical Examination Abnormalities</measure>
    <time_frame>Baseline, up to Day 168</time_frame>
    <description>Number of participants with change from baseline in physical examination abnormalities will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Change From Baseline in Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>Baseline, up to Day 168</time_frame>
    <description>Number of participants with change from baseline in ECG abnormalities will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Liver Fat Content</measure>
    <time_frame>Baseline, weeks 6, 12, 18 and 24</time_frame>
    <description>Percent change from baseline in liver fat content will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of JNJ-75220795 Over Time</measure>
    <time_frame>SAD: Predose, up to Day 3 and MAD: Predose, up to Day 86</time_frame>
    <description>Plasma samples will be analyzed to determine concentrations of JNJ-75220795.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment-emergent Anti Drug Antibodies (ADA)</measure>
    <time_frame>Up to Day 168</time_frame>
    <description>Percentage of participants with treatment-emergent ADA will be assessed using a validated assay for ADA analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in cohorts 1-5 and cohorts 3a-5a will receive subcutaneous (SC) injection of single dose (Part A) of JNJ-75220795 or matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose (MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in cohorts 6-8 will receive SC injection of 2 doses (Part B) of JNJ-75220795 or matching placebo. Participants in cohorts 9-11 will receive SC injection of 4 doses (Part C) of JNJ-75220795 or matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-75220795</intervention_name>
    <description>JNJ-75220795 will be administered subcutaneously.</description>
    <arm_group_label>Multiple Ascending Dose (MAD)</arm_group_label>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo will be administered subcutaneously.</description>
    <arm_group_label>Multiple Ascending Dose (MAD)</arm_group_label>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with certain genetic predisposition to non-alcoholic fatty liver disease&#xD;
             (NAFLD) determined at screening&#xD;
&#xD;
          -  Presence of liver steatosis at screening&#xD;
&#xD;
          -  Participants on anti-hypertensive and/or lipid lowering medications and/or glucose&#xD;
             lowering medications must be on stable dose(s) for at least 4 weeks prior to screening&#xD;
&#xD;
          -  Weight stable defined as no more than 5% body weight loss or gain within 3 months&#xD;
             prior to screening and no more than 5% body weight loss or gain from screening to&#xD;
             randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to JNJ-75220795 or its excipients&#xD;
&#xD;
          -  History of hepatitis B surface antigen (HbsAg) or hepatitis C antibody (anti-HCV)&#xD;
             positive, or other clinically active liver disease, or tests positive for HbsAg or&#xD;
             anti-HCV at screening&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV) antibody positive, or tests positive for&#xD;
             HIV at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Liver Health</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Arizona Liver Health</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Centers of America, LLC</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108997</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

